Alpha-Hydroxyisocaproic Acid Calcium (HICA)

### Introduction to Leucine Metabolism and Metabolite Generation

To understand the biochemical role of Alpha-Hydroxyisocaproic Acid (HICA), one must first examine the metabolic pathways of its parent compound, the essential branched-chain amino acid (BCAA) L-leucine. Leucine is widely recognized as the primary nutritional signal for the activation of the mechanistic target of rapamycin complex 1 (mTORC1), the master regulator of muscle protein synthesis (MPS). However, leucine's biological activity is not limited to its intact form; its metabolites also possess distinct physiological properties.

The initial step in leucine degradation occurs primarily in skeletal muscle, which, unlike the liver, contains high concentrations of the branched-chain aminotransferase (BCAT) enzyme. BCAT catalyzes the reversible transamination of leucine, transferring its alpha-amino group to alpha-ketoglutarate to form glutamate and the alpha-keto acid of leucine: alpha-ketoisocaproate (KIC).

Once KIC is formed, it sits at a metabolic crossroads and can undergo three distinct fates: 1. **Oxidation:** The majority of KIC is irreversibly oxidatively decarboxylated by the branched-chain alpha-keto acid dehydrogenase (BCKDH) complex within the mitochondria, eventually yielding acetyl-CoA and acetoacetate, which enter the citric acid cycle for ATP production. 2. **Conversion to HMB:** A small fraction (approximately 5%) of KIC is oxidized in the cytosol by the enzyme KIC dioxygenase to form beta-hydroxy beta-methylbutyrate (HMB), a well-known anti-catabolic supplement. 3. **Reduction to HICA:** An even smaller fraction of KIC is reduced to Alpha-Hydroxyisocaproic Acid (HICA), also known as leucic acid. This reversible reduction is catalyzed by enzymes such as lactate dehydrogenase (LDH) or specific hydroxyacid dehydrogenases, utilizing NADH as a reducing equivalent.

### The Anti-Catabolic Hypothesis: Metalloproteinase Inhibition

While intact leucine is primarily anabolic (stimulating MPS), its downstream metabolites, HMB and HICA, are generally classified as anti-catabolic (inhibiting muscle protein breakdown, MPB). The net protein balance in skeletal muscle is the difference between MPS and MPB. By suppressing MPB, HICA theoretically allows the basal or exercise-induced rates of MPS to yield a greater net positive protein balance, leading to muscle hypertrophy or preservation during caloric deficits.

The specific mechanism by which HICA exerts this anti-catabolic effect is distinct from HMB. HMB is known to inhibit the ubiquitin-proteasome system (UPS) and modulate the autophagy-lysosomal pathway. HICA, on the other hand, has been hypothesized to act primarily through the inhibition of matrix metalloproteinases (MMPs) and other proteolytic enzymes.

Metalloproteinases are a family of zinc-dependent endopeptidases responsible for the degradation of extracellular matrix proteins and various intracellular proteins. During intense eccentric exercise, mechanical tension and subsequent inflammation upregulate the activity of specific MMPs (such as MMP-2 and MMP-9) in skeletal muscle. While this proteolytic activity is a necessary component of the tissue remodeling and repair process, excessive or prolonged MMP activity exacerbates muscle damage, prolongs delayed onset muscle soreness (DOMS), and delays the restoration of force production.

In vitro and animal models have suggested that HICA can bind to the active sites of certain metalloproteinases, acting as a competitive inhibitor. By dampening the initial spike in proteolytic activity following exercise-induced muscle damage (EIMD), HICA is thought to reduce the severity of microtrauma, thereby attenuating DOMS and accelerating the recovery timeline.

### Modulation of the Inflammatory Response

Beyond direct enzyme inhibition, HICA may also modulate the localized inflammatory response to exercise. Muscle damage triggers the infiltration of neutrophils and macrophages into the muscle tissue. These immune cells release pro-inflammatory cytokines (such as TNF-alpha and IL-6) and reactive oxygen species (ROS) to clear cellular debris. While essential for regeneration, an exaggerated inflammatory response can lead to secondary muscle damage—where healthy, uninjured muscle fibers adjacent to the injury site are damaged by the oxidative and proteolytic environment.

By reducing the initial magnitude of extracellular matrix degradation via MMP inhibition, HICA may indirectly blunt the chemotactic signals that recruit excessive immune cells to the muscle. This results in a more controlled, efficient inflammatory phase, minimizing secondary muscle damage and preserving the structural integrity of the sarcolemma and contractile apparatus.

### mTORC1 Signaling and Anabolic Potential

While HICA is primarily viewed as an anti-catabolic agent, researchers have investigated whether it retains any of the anabolic signaling properties of its parent amino acid, leucine. Intact leucine activates mTORC1 by binding to Sestrin2, relieving its inhibitory effect on the GATOR2 complex, which ultimately leads to the activation of the Rag GTPases that recruit mTORC1 to the lysosomal surface for activation by Rheb.

Studies examining the direct effect of HICA on mTORC1 signaling are sparse, but current evidence suggests that HICA is a very weak agonist of this pathway compared to leucine. Because HICA lacks the alpha-amino group present in leucine, it cannot interact with the specific amino acid sensors (like Sestrin2) in the same manner. Therefore, HICA should not be viewed as a replacement for leucine or complete proteins in stimulating muscle protein synthesis. Its utility, if any, lies strictly in its ability to manage the degradation side of the protein turnover equation.

### Pharmacokinetics and the Role of the Calcium Salt

In its free acid form, alpha-hydroxyisocaproic acid is a liquid with poor stability and an extremely astringent, unpleasant taste. To make it viable for dietary supplementation, it is typically reacted with calcium carbonate or calcium hydroxide to form a stable, powdered salt: Alpha-Hydroxyisocaproic Acid Calcium (Calcium HICA).

Upon ingestion, the acidic environment of the stomach dissociates the calcium ion from the leucic acid molecule. The free HICA is then rapidly absorbed across the intestinal epithelium, likely via monocarboxylate transporters (MCTs) due to its structural similarity to lactate and other short-chain organic acids.

Once in the systemic circulation, HICA is taken up by skeletal muscle and other tissues. Because it is a naturally occurring intermediate in human metabolism, it is readily recognized by cellular transport mechanisms. The half-life of exogenous HICA in humans is not definitively established in the literature, but based on the kinetics of similar organic acids like KIC and HMB, plasma concentrations likely peak within 60 to 120 minutes post-ingestion and return to baseline within a few hours. This rapid clearance necessitates multiple daily doses (typically 500 mg taken three times daily) to maintain elevated plasma and intramuscular concentrations throughout the day.

### The Disconnect Between Theory and Clinical Reality

Despite the elegant biochemical rationale for HICA's use as an anti-catabolic and recovery-enhancing agent, the translation from theory to clinical efficacy has been fraught with inconsistency. Early pilot studies (such as Mero et al., 2010) provided proof-of-concept data showing that HICA supplementation could increase lean body mass and reduce DOMS in athletes undergoing intensive training.

However, the biochemical pathways described above operate within a highly complex, redundant system. Skeletal muscle has numerous overlapping mechanisms to regulate protein breakdown and inflammation. Inhibiting one specific pathway (e.g., MMPs via HICA) may simply result in the compensatory upregulation of another (e.g., the ubiquitin-proteasome system or calpains). This redundancy likely explains why more recent, rigorously controlled trials (such as Marques et al., 2019) have found no significant effect of HICA supplementation on body composition, muscle thickness, or performance adaptations when compared to a placebo. When total daily protein intake is adequate, the endogenous production of leucine metabolites (including HICA) may already be maximized, rendering exogenous supplementation superfluous.